Mirvetuximab Fails to Boost Survival in Platinum-Eligible OC

by admin | Jun 25, 2026 | Health

Spread the love

Mirvetuximab has come up short in the first randomized trial testing an antibody-drug conjugate plus standard carboplatin for patients with platinum-sensitive ovarian cancer.
Medscape Medical News

← Palbociclib Gains HER2+ Breast Cancer Maintenance Indication The political painting that is still on trial in South Korea →

Written By

Written by Albert Pham, News Curator and Blogger

Cocaine Trade Booms Despite U.S. Airstrikes and Drug Crackdown

Oct 13, 2026 | albertpham, Economy_finances, Health

The global cocaine trade continues to expand despite U.S. airstrikes against suspected smugglers. Discover why trafficking networks remain resilient.

McDonald’s Chicken and Beverage Strategy: Global Growth Plans Through 2030

Oct 12, 2026 | albertpham, Economy_finances, Health

McDonald’s is expanding its chicken menu and specialty beverages to gain market share by 2030, challenge competitors and attract more customers.

Endometriosis in Canada: Why Women Are Seeking Treatment in Mexico

Oct 12, 2026 | albertpham, Health, Travel

Canadian women are travelling to Mexico for endometriosis treatment after facing long wait times, highlighting gaps in specialist care and women’s health services.

Mirvetuximab Fails to Boost Survival in Platinum-Eligible OC

Written By

Related Posts

Cocaine Trade Booms Despite U.S. Airstrikes and Drug Crackdown

McDonald’s Chicken and Beverage Strategy: Global Growth Plans Through 2030

Endometriosis in Canada: Why Women Are Seeking Treatment in Mexico

0 Comments

Explore More

Connect With Us

Quick Links

Legal

Stay Updated